All In Biotech

Drug Trial Radar · NCT03237182

The Individualized M(X) Drug-resistant TB Treatment Strategy Study

The Individualized M(X) Drug-resistant TB Treatment Strategy Study A Strategy to Improve Treatment Outcomes in Patients With Drug-resistant TB

Last checked: Nov 20, 2026Latest source record: Sep 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 205 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

205

Actual

Start

Jun 14, 2017

Primary completion

Dec 19, 2022

Study completion Dec 19, 2022

Sponsor

Sponsor type
Research network
First posted
Aug 2, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized controlled clinical trial comparing treatment success of a gene-derived individualized drug-resistant Tuberculosis regimen to a standard Tuberculosis regimen based on South African National Tuberculosis guidelines.

Conditions

  • Tuberculosis, Multidrug-Resistant

Interventions

  • Individualized TB treatment with multiple drugsDrug

    Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing: rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone

  • Standardized TB treatment with multiple drugsDrug

    Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines: rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Culture negative survival rateTime frame: 24 months
  2. Culture negative survival rateTime frame: 30 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • King Dinuzulu Hospital

    Durban, KwaZulu-Natal, South Africa

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.